The AP (4/5, Johnson) reports the FDA approved Supernus Pharmaceuticals’ Qelbree (viloxazine) for the treatment of children with AD/HD. Unlike most alternatives, “Qelbree is not a stimulant or a controlled substance, making it harder to abuse than older drugs,” which has been an issue for other AD/HD drugs. The AP adds that “viloxazine was sold as an antidepressant in Europe for several decades, but was never approved by the FDA.”
The Hill (4/5, Choi) reports viloxazone is the first new drug approved by the FDA to treat children with AD/HD in more than a decade.
Related Links:
— “FDA Approves New Drug For Children With AD/HD “Linda A. Johnson, AP, April 5, 2021